BACKGROUND At present,the clinical mechanisms underlying precocious puberty remain unclear,making effective intervention for children experiencing this condition and rapidly progressive puberty essential.AIM To explor...BACKGROUND At present,the clinical mechanisms underlying precocious puberty remain unclear,making effective intervention for children experiencing this condition and rapidly progressive puberty essential.AIM To explore the effects of Zhibai dihuang pills and gonadotropin-releasing hormone analogue(GnRHa)on growth and ovarian function in girls with precocious puberty.METHODS The clinical data of 84 adolescent girls with precocious puberty and rapidly progressive puberty from February 2017 to August 2023 were retrospectively analyzed.Girls were divided into a control group and an observation group,with 42 cases in each group.The control group received diet intervention combined with GnRHa treatment,while the observation group received diet intervention combined with Zhibai dihuang pills+GnRHa treatment.Outcomes such as clinical efficacy,growth indicators,ovarian function,and adverse reactions were compared between the two groups.RESULTS The observation group showed superior clinical efficacy compared to the control group(P<0.05).Prior to the intervention,no significant differences were found in growth or ovarian function between the groups(P>0.05).Post-intervention,the observation group exhibited significantly lower rates in growth,height,and bone age,along with reduced levels of progesterone,testosterone,estradiol,prolactin,luteinizing hormone,and follicle-stimulating hormone compared to the control group(P<0.05).The incidence of adverse reactions was similar across both groups(P>0.05).CONCLUSION Combining Zhibai dihuang pills with GnRHa and dietary intervention effectively improves growth,enhances ovarian function,and minimizes adverse reactions in adolescent girls with precocious and rapidly progressive puberty.展开更多
Aim： To study the effect and mechanism of gonadotrophin-releasing hormone （GnRH） on murine Leydig cell steroidogenesis. Methods： Purified murine Leydig cells were treated with GnRH-Ⅰ and -Ⅱ agonists, and testost...Aim： To study the effect and mechanism of gonadotrophin-releasing hormone （GnRH） on murine Leydig cell steroidogenesis. Methods： Purified murine Leydig cells were treated with GnRH-Ⅰ and -Ⅱ agonists, and testosterone production and steroidogenic enzyme expressions were determined. Results： GnRH-Ⅰ and -Ⅱ agonists significantly stimulated murine Leydig cell steroidogenesis 60%-80% in a dose- and time-dependent manner （P 〈 0.05）. The mRNA expressions of steroidogenic acute regulatory （STAR） protein, P450scc, 3β-hydroxysteroid dehydrogenase （HSD）, but not 17β-hydroxylase or 17β-HSD, were significantly stimulated by both GnRH agonists with a 1.5- to 3-fold increase （P 〈 0.05）. However, only 3β-HSD protein expression was induced by both GnRH agonists, with a 1.6- to 2-fold increase （P 〈 0.05）. Conclusion： GnRH directly stimulated murine Leydig cell steroidogenesis by activating 3β-HSD enzyme expression.展开更多
目的探讨重组人生长激素(recombinant human growth hormone,rhGH)联合促性腺激素释放激素类似物(gonadotropin releasing hormone analogue,GnRHa)对青春期特发性身材矮小症(idiopathic short stature,ISS)男童身高及骨代谢水平的影响...目的探讨重组人生长激素(recombinant human growth hormone,rhGH)联合促性腺激素释放激素类似物(gonadotropin releasing hormone analogue,GnRHa)对青春期特发性身材矮小症(idiopathic short stature,ISS)男童身高及骨代谢水平的影响。方法选取2020年10月至2021年9月上饶市立医院收治的60例ISS男童作为研究对象,采用随机数字表法分为对照组与观察组,每组30例。对照组给予rhGH治疗,观察组给予rhGH联合GnRHa治疗。比较两组治疗前后生长参数[身高(height,Ht)、体质量(weight,Wt)、体重指数(body mass index,BMI)、生长速率(growth velocity,GV)、身高标准差积分(height standard deviation score,HtSDS)]、骨代谢指标{血清骨碱性磷酸酶(bone alkaline phosphatase,BAP)、胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)、25-羟维生素D[25-hydroxyvitaminD,25-(OH)D]}、血脂指标[总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、动脉粥样硬化指数(atherosclerosis index,AI)]及用药安全性。结果治疗12个月后,两组Ht、BMI、HtSDS均高于治疗前,Wt大于治疗前,GV快于治疗前,且观察组Ht、BMI、HtSDS均高于对照组,Wt大于对照组,GV快于对照组,差异有统计学意义(P<0.05)。治疗12个月后,两组BAP、IGF-1、25-(OH)D水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗12个月后,两组HDL-C水平均高于治疗前,LDL-C水平、AI均低于治疗前,且观察组HDL-C水平高于对照组,LDL-C水平、AI均低于对照组,差异有统计学意义(P<0.05);两组组内、组间治疗前与治疗12个月后TC、TG水平比较差异无统计学意义。两组不良反应发生率比较差异无统计学意义。结论rhGH联合GnRHa治疗ISS男童可改善患儿骨代谢及血脂水平,促进其生长发育,安全性较高。展开更多
文摘BACKGROUND At present,the clinical mechanisms underlying precocious puberty remain unclear,making effective intervention for children experiencing this condition and rapidly progressive puberty essential.AIM To explore the effects of Zhibai dihuang pills and gonadotropin-releasing hormone analogue(GnRHa)on growth and ovarian function in girls with precocious puberty.METHODS The clinical data of 84 adolescent girls with precocious puberty and rapidly progressive puberty from February 2017 to August 2023 were retrospectively analyzed.Girls were divided into a control group and an observation group,with 42 cases in each group.The control group received diet intervention combined with GnRHa treatment,while the observation group received diet intervention combined with Zhibai dihuang pills+GnRHa treatment.Outcomes such as clinical efficacy,growth indicators,ovarian function,and adverse reactions were compared between the two groups.RESULTS The observation group showed superior clinical efficacy compared to the control group(P<0.05).Prior to the intervention,no significant differences were found in growth or ovarian function between the groups(P>0.05).Post-intervention,the observation group exhibited significantly lower rates in growth,height,and bone age,along with reduced levels of progesterone,testosterone,estradiol,prolactin,luteinizing hormone,and follicle-stimulating hormone compared to the control group(P<0.05).The incidence of adverse reactions was similar across both groups(P>0.05).CONCLUSION Combining Zhibai dihuang pills with GnRHa and dietary intervention effectively improves growth,enhances ovarian function,and minimizes adverse reactions in adolescent girls with precocious and rapidly progressive puberty.
文摘Aim： To study the effect and mechanism of gonadotrophin-releasing hormone （GnRH） on murine Leydig cell steroidogenesis. Methods： Purified murine Leydig cells were treated with GnRH-Ⅰ and -Ⅱ agonists, and testosterone production and steroidogenic enzyme expressions were determined. Results： GnRH-Ⅰ and -Ⅱ agonists significantly stimulated murine Leydig cell steroidogenesis 60%-80% in a dose- and time-dependent manner （P 〈 0.05）. The mRNA expressions of steroidogenic acute regulatory （STAR） protein, P450scc, 3β-hydroxysteroid dehydrogenase （HSD）, but not 17β-hydroxylase or 17β-HSD, were significantly stimulated by both GnRH agonists with a 1.5- to 3-fold increase （P 〈 0.05）. However, only 3β-HSD protein expression was induced by both GnRH agonists, with a 1.6- to 2-fold increase （P 〈 0.05）. Conclusion： GnRH directly stimulated murine Leydig cell steroidogenesis by activating 3β-HSD enzyme expression.
文摘目的探讨重组人生长激素(recombinant human growth hormone,rhGH)联合促性腺激素释放激素类似物(gonadotropin releasing hormone analogue,GnRHa)对青春期特发性身材矮小症(idiopathic short stature,ISS)男童身高及骨代谢水平的影响。方法选取2020年10月至2021年9月上饶市立医院收治的60例ISS男童作为研究对象,采用随机数字表法分为对照组与观察组,每组30例。对照组给予rhGH治疗,观察组给予rhGH联合GnRHa治疗。比较两组治疗前后生长参数[身高(height,Ht)、体质量(weight,Wt)、体重指数(body mass index,BMI)、生长速率(growth velocity,GV)、身高标准差积分(height standard deviation score,HtSDS)]、骨代谢指标{血清骨碱性磷酸酶(bone alkaline phosphatase,BAP)、胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)、25-羟维生素D[25-hydroxyvitaminD,25-(OH)D]}、血脂指标[总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、动脉粥样硬化指数(atherosclerosis index,AI)]及用药安全性。结果治疗12个月后,两组Ht、BMI、HtSDS均高于治疗前,Wt大于治疗前,GV快于治疗前,且观察组Ht、BMI、HtSDS均高于对照组,Wt大于对照组,GV快于对照组,差异有统计学意义(P<0.05)。治疗12个月后,两组BAP、IGF-1、25-(OH)D水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗12个月后,两组HDL-C水平均高于治疗前,LDL-C水平、AI均低于治疗前,且观察组HDL-C水平高于对照组,LDL-C水平、AI均低于对照组,差异有统计学意义(P<0.05);两组组内、组间治疗前与治疗12个月后TC、TG水平比较差异无统计学意义。两组不良反应发生率比较差异无统计学意义。结论rhGH联合GnRHa治疗ISS男童可改善患儿骨代谢及血脂水平,促进其生长发育,安全性较高。
